Current reports
6-K
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
24 Apr 24
6-K
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
24 Apr 24
6-K
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
24 Apr 24
6-K
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
16 Apr 24
6-K
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
4 Apr 24
6-K
CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock
17 Jan 24
6-K
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development
5 Jan 24
6-K
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
19 Dec 23
6-K
Current report (foreign)
14 Nov 23
6-K
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
14 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
9 Feb 23
424B4
Prospectus supplement with pricing info
6 Feb 23
F-3ASR
Automatic shelf registration (foreign)
17 Sep 21
424B4
Prospectus supplement with pricing info
29 Jan 21
F-1
Registration statement (foreign)
25 Jan 21
DRS
Draft registration statement
27 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Aug 20
424B4
Prospectus supplement with pricing info
14 Aug 20
S-8
Registration of securities for employees
14 Aug 20
8-A12B
Registration of securities on exchange
13 Aug 20
Proxies
No filings
Other
UPLOAD
Letter from SEC
19 Oct 23
CORRESP
Correspondence with SEC
10 Oct 23
UPLOAD
Letter from SEC
26 Sep 23
EFFECT
Notice of effectiveness
28 Jan 21
CORRESP
Correspondence with SEC
25 Jan 21
CORRESP
Correspondence with SEC
25 Jan 21
UPLOAD
Letter from SEC
1 Dec 20
EFFECT
Notice of effectiveness
14 Aug 20
CERT
Certification of approval for exchange listing
13 Aug 20
CORRESP
Correspondence with SEC
11 Aug 20
Ownership
144
Notice of proposed sale of securities
12 Apr 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
GSK plc
6 Feb 24
144
Notice of proposed sale of securities
5 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
27 Mar 23
SC 13D/A
Hothum Mathias
24 Feb 23
SC 13D/A
von Bohlen und Halback Friedrich
24 Feb 23